Pfiz­er pulls sick­le cell drug from all mar­kets af­ter da­ta re­view showed rise in deaths and com­pli­ca­tions

Pfiz­er said it will with­draw its sick­le cell dis­ease treat­ment Oxbry­ta from all mar­kets world­wide, af­ter da­ta showed an “im­bal­ance” of fa­tal­i­ties and com­pli­ca­tions com­mon …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER